About A-type potassium channel modulatory protein KCNIP2
A-type potassium channel modulatory protein KCNIP2 (KCNIP2) is a protein
from Homo sapiens identified by UniProt accession
Q9NS61, 270 residues long.
MolForge cross-references it against 0 known binders and
162 disease associations.
Target properties
| Protein name | A-type potassium channel modulatory protein KCNIP2 |
|---|
| UniProt accession | Q9NS61 |
|---|
| Gene | KCNIP2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 270 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (162)
Diseases linked to this target (Open Targets).
- heel bone mineral density · score 0.27
- breast adenocarcinoma · score 0.22
- self reported educational attainment · score 0.17
- apolipoprotein A 1 measurement · score 0.16
- atrial fibrillation · score 0.15
- diet measurement · score 0.13
- alkaline phosphatase measurement · score 0.12
- verbal-numerical reasoning measurement · score 0.12
- mathematical ability · score 0.11
- platelet-to-lymphocyte ratio · score 0.09
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9NS61-F1 | alphafold | PREDICTED | 69.33 | — |
Amino-acid sequence (270 residues)
MRGQGRKESL SDSRDLDGSY DQLTGHPPGP TKKALKQRFL KLLPCCGPQA LPSVSETLAA PASLRPHRPR LLDPDSVDDE FELSTVCHRP EGLEQLQEQT KFTRKELQVL YRGFKNECPS GIVNEENFKQ IYSQFFPQGD SSTYATFLFN AFDTNHDGSV SFEDFVAGLS VILRGTVDDR LNWAFNLYDL NKDGCITKEE MLDIMKSIYD MMGKYTYPAL REEAPREHVE SFFQKMDRNK DGVVTIEEFI ESCQKDENIM RSMQLFDNVI
Explore A-type potassium channel modulatory protein KCNIP2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets